Start for free
Start for free
Monograph Capital logo

Monograph Capital

Europe, England, United Kingdom, London

Description

Monograph Capital is a life sciences venture firm.

Investor Profile

Monograph Capital has made 12 investments, with 3 in the past 12 months and 42% as lead.

Stage Focus

  • Series A (50%)
  • Series B (42%)
  • Series C (8%)

Country Focus

  • United States (50%)
  • United Kingdom (33%)
  • Canada (8%)
  • Singapore (8%)

Industry Focus

  • Biotechnology
  • Health Care
  • Life Science
  • Medical
  • Therapeutics
  • Information Technology
  • Biopharma
  • Product Research
  • Artificial Intelligence (Ai)
  • Machine Learning
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Monograph Capital frequently co-invest with?

Eventide
Eventide
North America, Massachusetts, United States, Boston
Co-Investments: 2
Samsara BioCapital
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 2
Advent Life Sciences
Advent Life Sciences
Europe, England, United Kingdom, London
Co-Investments: 2
New Enterprise Associates
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 2
LifeArc Ventures
LifeArc Ventures
Europe, England, United Kingdom, London
Co-Investments: 2
TPG
TPG
North America, California, United States, San Francisco
Co-Investments: 3
Business Growth Fund
Business Growth Fund
Europe, England, United Kingdom, London
Co-Investments: 2
Dementia Discovery Fund
Dementia Discovery Fund
Europe, England, United Kingdom, London
Co-Investments: 2
F-Prime Capital
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Enavate Sciences
Enavate Sciences
North America, New York, United States, New York
Co-Investments: 2

What are some of recent deals done by Monograph Capital?

Maxion Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Maxion Therapeutics helps in learning transformative therapies.

Information TechnologyTherapeutics
Series AMar 17, 2025
Amount Raised: $75,016,620
Ouro Medicines

San Francisco, California, United States

Ouroboros Medicines is a biotechnology company specializes in immunology.

BiotechnologyHealth CareMedical
Series AJan 10, 2025
Amount Raised: $120,000,000
Autobahn Therapeutics

San Diego, California, United States

Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.

BiotechnologyHealth CareLife ScienceTherapeutics
Series CJul 24, 2024
Amount Raised: $100,000,000
Nocion Therapeutics

Cambridge, Massachusetts, United States

Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.

BiotechnologyHealth CareMedical
Series BMar 4, 2024
Amount Raised: $62,000,000
Sudo Biosciences

Carmel, Indiana, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

BiopharmaBiotechnologyHealth CareLife ScienceMedical
Series BFeb 13, 2024
Amount Raised: $30,000,000
Sudo Biosciences

Carmel, Indiana, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

BiopharmaBiotechnologyHealth CareLife ScienceMedical
Series BDec 20, 2023
Amount Raised: $116,000,000
ODAIA

Toronto, Ontario, Canada

ODAIA is driving next-generation customer engagement with the leading AI-fueled Customer Data Platform for the Life Sciences industry.

Artificial Intelligence (AI)BiotechnologyMachine LearningSoftware
Series BMay 1, 2023
Amount Raised: $25,000,000
Maxion Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Maxion Therapeutics helps in learning transformative therapies.

Information TechnologyTherapeutics
Series AFeb 15, 2023
Amount Raised: $15,648,002
RegASK

Singapore, Central Region, Singapore

RegASK is global RegTech company using artificial intelligence for augmenting regulatory research and ESG issues management.

Information TechnologyProfessional ServicesSaaS
Series ADec 16, 2022
Amount Raised: $10,000,000
HI-Bio

South San Francisco, California, United States

Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.

BiotechnologyLife ScienceMedicalProduct ResearchTherapeutics
Series ANov 1, 2022
Amount Raised: $120,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator